Dear Sir, As required under Regulation 47(3) of SEBI (LODR), Regulations, 2015. Please find the attached News Paper Publication made towards our issued Quarterly Results for Dec-25. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd has submitted newspaper clippings of its un-audited financial results for the quarter ended 31 December 2025, published in Free Press Journal and Navshakti on 25 January 2026, as required under SEBI LODR Regulation 47(3). Revenue from operations stood at Rs. 150.95 lakhs in Q3 FY26, marginally lower than Rs. 154.39 lakhs in Q3 FY25. For the nine months ended December 2025, revenue declined to Rs. 469.81 lakhs from Rs. 529.86 lakhs in the same period last year. Net profit after tax improved to Rs. 8.36 lakhs in Q3 FY26 from Rs. 5.33 lakhs in Q3 FY25, though for the nine-month period it was nearly flat at Rs. 34.33 lakhs versus Rs. 34.62 lakhs. Basic and diluted EPS for Q3 stood at Rs. 0.33 (vs Rs. 0.21 YoY) and at Rs. 1.36 for the nine months (vs Rs. 1.37 YoY). The results were reviewed by the Audit Committee and approved by the Board on 24 January 2026, with statutory auditors issuing an unqualified opinion.
Mixed signals for shareholders: while Q3 net profit showed healthy YoY growth despite a slight revenue dip, the nine-month revenue decline of around 11% suggests top-line pressure. The stock may see limited reaction given the very small scale of operations and absolute numbers involved.